Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antibiotic Selection00:57

Antibiotic Selection

56.0K
Overview
56.0K
Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

64
Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
64
Urine Studies II: Urine Culture and Sensitivity Test01:26

Urine Studies II: Urine Culture and Sensitivity Test

175
A urine culture and sensitivity test is a diagnostic procedure used to identify urinary tract bacterial infections and determine the most effective antibiotics for treatment. This test is generally preferred when a patient shows manifestations of a urinary tract infection, such as frequent or painful urination, cloudy or foul-smelling urine, or lower abdominal pain.Purpose of the TestThe primary goals of a urine culture and sensitivity test are to:Determine the specific bacteria causing the...
175
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

5.0K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
5.0K
Pneumonia IV: Management01:28

Pneumonia IV: Management

483
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
483
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care01:30

Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care

60
A healthcare provider can diagnose a urinary tract infection (UTI) through several methods:Medical History and Symptoms: The provider will take a detailed medical history and ask about symptoms such as frequent urination, burning sensation during urination, and lower abdominal pain.Urinalysis: A clean-catch urine sample is collected in a sterile container and tested for the presence of bacteria, white blood cells (leukocytes), nitrites, blood, and protein. The presence of leukocytes and...
60

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antibiotic use in serious infections.

Current opinion in critical care·2026
Same author

Optimal antibiotic use in the intensive care unit.

Critical care (London, England)·2025
Same author

Cost Implication of Inappropriate Empiric Antibiotics in Gram-Negative Infections.

Hospital pharmacy·2024
Same author

Preventing New Gram-negative Resistance Through Beta-lactam De-escalation in Hospitalized Patients With Sepsis: A Retrospective Cohort Study.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2024
Same author

Comparison of Empiric Antibiotic Treatment Regimens for Hospitalized, Non-severe Community-acquired Pneumonia: A Retrospective, Multicenter Cohort Study.

Clinical therapeutics·2024
Same author

Evaluation of an individual examination remediation policy in a professional pharmacy course.

Currents in pharmacy teaching & learning·2023

Related Experiment Video

Updated: Oct 3, 2025

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

13.0K

Antibiotic Optimization in the Intensive Care Unit.

Bryan D Lizza1, Nick Raush1,2, Scott T Micek1,3

  • 1Barnes Jewish Hospital, Saint Louis, Missouri.

Seminars in Respiratory and Critical Care Medicine
|February 16, 2022
PubMed
Summary

Optimizing antimicrobial dosing in critically ill patients is crucial due to altered pharmacokinetics. Strategies like continuous infusions and therapeutic drug monitoring aim to improve outcomes and reduce toxicity, but implementation challenges remain.

More Related Videos

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method
12:03

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method

Published on: April 18, 2019

26.6K
Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE
03:22

Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE

Published on: March 1, 2024

554

Related Experiment Videos

Last Updated: Oct 3, 2025

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

13.0K
Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method
12:03

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method

Published on: April 18, 2019

26.6K
Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE
03:22

Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE

Published on: March 1, 2024

554

Area of Science:

  • Critical care medicine
  • Pharmacology
  • Infectious diseases

Background:

  • Effective antimicrobial therapy is vital for critically ill patients with infections like pneumonia and sepsis.
  • Altered pharmacokinetics and pharmacodynamics (PK/PD) in critical illness complicate antimicrobial dosing, leading to potential treatment failure or toxicity.
  • Commonly used antimicrobials such as vancomycin and beta-lactams require careful dose optimization.

Purpose of the Study:

  • To review strategies for optimizing antimicrobial dosing in critically ill patients.
  • To discuss the challenges and benefits of extended or continuous infusion (EI/CI) and therapeutic drug monitoring (TDM) for vancomycin and beta-lactams.
  • To highlight the need for individualized dosing strategies based on patient factors.

Main Methods:

  • Review of available data on vancomycin and beta-lactam administration in critically ill patients.
  • Analysis of strategies including extended infusion (EI), continuous infusion (CI), and therapeutic drug monitoring (TDM).
  • Discussion of pharmacokinetic/pharmacodynamic (PK/PD) principles and their application in critical care.

Main Results:

  • Continuous infusion (CI) of vancomycin may reduce nephrotoxicity without compromising efficacy, though data is largely retrospective.
  • Transitioning vancomycin TDM from trough-based to area-under-the-curve:minimum inhibitory concentration (AUC:MIC) ratios shows potential for reduced nephrotoxicity but faces implementation barriers.
  • Therapeutic drug monitoring (TDM) for beta-lactams like piperacillin-tazobactam, cefepime, and meropenem could improve time above minimum inhibitory concentration (T >MIC), but lacks commercial assays and robust clinical evidence.

Conclusions:

  • Optimizing antimicrobial dosing in critical illness is essential to balance efficacy and safety.
  • Extended or continuous infusion and TDM are strategies to manage altered PK/PD, but require careful consideration of available evidence and implementation challenges.
  • Individualized dosing strategies tailored to patient-specific factors are crucial for reducing treatment failure and toxicity in critically ill patients.